Maternal and Newborn Vitamin D-Binding Protein, Vitamin D Levels, Vitamin D Receptor Genotype, and Childhood Type 1 Diabetes by Tapia, German et al.
Maternal and Newborn Vitamin D-Binding Protein, Vitamin D levels, Vitamin D 
Receptor genotype, and Childhood Type 1 Diabetes  
German Tapia, Ph.D 1, Karl Mårild, Ph.D 1, Sandra R. Dahl, Ph.D 2, Nicolai A. Lund-
Blix, Ph.D 1,3,4, Marte K. Viken, Ph.D 5, Benedicte A. Lie, Ph.D 5,6, Pål R. Njølstad, 
Ph.D, M.D 7,8, Geir Joner, Ph.D, M.D 4,9, Torild Skrivarhaug, Ph.D, M.D 4,9, Arieh S. 
Cohen, Ph.D 10, Ketil Størdal, Ph.D, M.D 1, 11, Lars C. Stene, Ph.D 1. 
Affiliations 
1 Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, 
Oslo, Norway 
2 Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital, 
Aker, Oslo, Norway 
3 Barbara Davis Center for Diabetes, University of Colorado, Anschutz Medical 
Campus, Aurora, Colorado, USA 
4 Division of Pediatric and Adolescent Medicine, Oslo University Hospital, Oslo, 
Norway 
5 Department of Immunology, Rikshospitalet, Oslo University Hospital, Oslo, Norway 
6 Department of Medical Genetics, University of Oslo, Oslo, Norway 
7 Department of Pediatric and Adolescent Medicine, Haukeland University Hospital, 
Bergen, Norway 
8 KG Jebsen Center for Diabetes Research, Department of Clinical Science, University 
of Bergen, Bergen, Norway 
9 Institute of Clinical Medicine, University of Oslo, Oslo, Norway 
10 Department of Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark 
11 Pediatric Department, Østfold Hospital Trust, Grålum, Norway 
Corresponding author: German Tapia, Department of Chronic Diseases and Ageing, 
Norwegian Institute of Public Health, P.O. Box 222 Skøyen, NO-0213 Oslo, Norway. 
E-mail: german.tapia@fhi.no 
Running short title: Vitamin D-Binding Protein, VDR genotype and T1D 
Word count: 3270 (abstract 250), 39 references.  
Number of figures, tables: 2 Figures, 2 Tables. 
Online-only supplement with 2 Figures, 3 Tables.   
Keywords: Vitamin D, Vitamin D binding protein, Type 1 diabetes, Pregnancy, 
Genetics, rs11568820, Childhood, Norwegian Mother and Child Cohort  
Abstract 
Objective 
Circumstantial evidence links 25-hydroxyvitamin D (25[OH]D), vitamin D-Binding 
Protein (DBP), vitamin D-associated genes and type 1 diabetes (T1D), but no studies 
have jointly analyzed these. We aimed to investigate whether DBP levels during 
pregnancy or at birth were associated with offspring T1D, and whether vitamin D 
pathway genetic variants modified associations between DBP, 25(OH)D and T1D. 
Research Design and Methods 
From a cohort of >100,000 mother/child-pairs, we analyzed 189 pairs where the child 
later developed T1D, and 576 random control pairs. We measured 25(OH)D using 
LC-MS/MS, and DBP using polyclonal radioimmunoassay, in cord blood and 
maternal plasma samples collected at delivery and mid-pregnancy. We genotyped 
mother and child for variants in or near genes involved in vitamin D metabolism (GC, 
DHCR7, CYP2R1, CYP24A1, CYP27B1, VDR). Logistic regression was used to 
estimate odds ratios adjusted for potential confounders (aORs).  
Results 
Higher maternal DBP levels at delivery, but not in other samples, were associated 
with lower offspring T1D risk (OR=0.86, 95%CI: 0.74-0.98, per µM/L increase). 
Higher cord blood 25(OH)D levels were associated with lower T1D risk (OR=0.87, 
95%CI: 0.77-0.98 per 10 nmol/L increase) in children carrying the VDR rs11568820 
G/G genotype (P[interaction]=0.01 between 25(OH)D level and rs11568820). We did 
not detect other gene-environment interactions.  
Conclusions  
Higher maternal DBP level at delivery may decrease offspring T1D risk. Increased 
25(OH)D levels at birth may decrease T1D risk, depending on VDR genotype. These 
findings should be replicated in other studies. Future studies of vitamin D and T1D 




Type 1 diabetes (T1D) often presents in childhood and is associated with increased 
mortality (1). Vitamin D, vitamin D receptor (VDR), vitamin D-binding protein (DBP) 
and genetic polymorphisms associated with vitamin D metabolism have separately 
been suggested to influence the risk of T1D development (2). No studies have jointly 
analyzed vitamin D, DBP and genetic polymorphisms, which is necessary to relate 
any, or all, of these factors to T1D risk.  
Vitamin D is converted in the liver to 25-hydroxyvitamin D (25(OH)D), the clinical 
biomarker of vitamin D status (2). A second hydroxylation to the biologically active 
form calcitriol (1,25(OH)2D) occurs in the kidneys, and probably in other target cells.  
The biological effects of 1,25(OH)2D are mediated by vitamin D Receptor (VDR, 
encoded by VDR) (3). A recent study reported an association between 25(OH)D in 
early childhood and later islet autoimmunity (a surrogate endpoint for T1D) which 
depended on VDR genotype (4). VDR binding sites are overrepresented near genetic 
regions associated with T1D (5), and several single nucleotide polymorphisms (SNP) 
in or near genes involved in the vitamin D pathway (CYP2R1, CYP27B1 and DHCR7) 
have been associated with T1D (6). These SNPs, and SNPs in or near genes 
encoding Vitamin D-binding protein (DBP, encoded by GC) influence circulating 25-
hydroxyvitamin D (25(OH)D) concentration (7). We recently reported no association 
between 25(OH)D status and offspring T1D risk (8). In this study, we aimed to 
investigate whether the association may be modified by vitamin D pathway and VDR 
SNPs.  
DBP is a multifunctional protein that is the major carrier of vitamin D and its 
metabolites in the circulation, and is the precursor of the macrophage activating 
factor Gc-MAF (9). The circulating DBP concentration nearly doubles during 
pregnancy (10), and DBP appears to increase plasma half-life of 25(OH)D (11). It is 
not yet established whether the free fraction of 25(OH)D is a better marker for 
25(OH)D status than the total 25(OH)D level (12). Lower DBP levels in sera from 
patients with T1D compared to controls  have been reported (13), and recent studies 
suggest that DBP is a possible autoantigen in T1D (14; 15). Only one previous study 
has investigated maternal DBP during pregnancy and offspring T1D risk, reporting 
higher maternal DBP to be associated with lower offspring T1D risk (10). 
We aimed to jointly study maternal and newborn DBP, 25(OH)D and SNPs in the 
vitamin D pathway to test the following hypotheses: 1) Higher maternal or newborn 
DBP levels predict lower risk of childhood T1D and 2) The association between 
maternal or newborn 25(OH)D (or DBP) and childhood T1D risk is modified by 
genetic variants in the vitamin D pathway (including VDR). In addition, we 
hypothesized that a higher maternal or offspring 25(OH)D relative to DBP (surrogate 
for free 25[OH]D) predicts lower risk of childhood T1D.   
Methods 
Study sample 
We designed a nested case-control study in the Norwegian Mother and Child Cohort 
Study (MoBa) (16), which recruited ~114,000 pregnant mothers (41% eligible 
mothers participated) nationwide from 1999-2008 (last birth in 2009). The current 
study uses data from repeated questionnaires (using version VIII of the MoBa 
datafiles) and biomarker analyses of maternal and cord blood samples (17). All 
participating mothers gave written informed consent. The establishment and data 
collection in MoBa was previously based on a licence from the Norwegian Data 
Inspectorate and approval from The Regional Committee for Medical Research 
Ethics. It is now based on regulations related to the Norwegian Health Registry Act. 
The Regional Committee for Medical Research Ethics approved the current study. 
Children who developed T1D by February 5, 2014 were identified with a high degree 
of ascertainment by register linkage to the Norwegian Childhood Diabetes Registry 
(18). In all, 189 mother/child-pairs were T1D cases, and 576 mother/child-pairs from 
a random sample with available blood samples of the cohort were used as controls 
(Figure 1). Characteristics of the study participants in analysis are given in Table 1. 
Baseline characteristics for those with available blood samples were largely similar to 
the whole MoBa cohort, with the exception of a lower proportion of caesarean section 
and premature birth (19).  
 
Blood sampling  
Maternal blood samples were collected in EDTA tubes at hospital laboratories at 
enrolment around pregnancy week 18 (median 18.5, interquartile range (IQR) 19.4 – 
17.9 weeks) and again soon after delivery (median 1 day, IQR 3 – 1 days; hereafter 
referred to as postpartum). Plasma was separated before overnight shipment to the 
MoBa biobank. Immediately after birth, a blood sample was taken from the umbilical 
cord vein, shipped and plasma separated upon arrival. All samples were stored at -
80C until analysis (20).  
 
Laboratory assays of DBP and 25(OH)D 
Plasma concentration of DBP was determined using a competitive 
radioimmunoassay at the Oslo University Hospital Hormone Laboratory (Oslo, 
Norway) with a polyclonal antibody (anti-Gc-globulin, Dako, Glostrup, Denmark) and 
purified Gc-globulin (Sigma Chemicals, St. Louis, MO), as described previously (19). 
Analyzes of plasma 25-hydroxyvitamin D3 and –D2 were done at the internationally 
certified Statens Serum Institut (Copenhagen, Denmark), using a liquid 
chromatography tandem mass spectrometry (LC-MS/MS) and the MSMS Vitamin D 
kit (PerkinElmer, Inc., Waltham, MA) for mass spectrometry, as described previously 
(8). The seasonally adjusted (deseasonalized using cosinor modelling as described 
in (21)) sum of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3  was used as the 
exposure variable (hereafter referred to as 25(OH)D).  
 
Genotyping assays and genetic risk scores 
To account for established T1D susceptibility markers, participants were genotyped 
for selected SNPs using a custom Illumina Golden Gate assay (Illumina, San Diego, 
CA), as described in detail in (22). Briefly, SNPs in the vitamin D pathway (see 
Supplemental Table S1) were genotyped: five SNPs in or near CYP2R1, CYP24A1, 
CYP27B1, GC and DHCR7, associated with 25-hydroxyvitamin D (7), and two SNPs 
in or near VDR (rs1544410, rs11568820). A vitamin D deficiency genotype score for 
the mother and child was calculated by summing the risk alleles across five non-VDR 
SNPs (7). Human leukocyte antigen (HLA) class II genotype was imputed using the 
HLA*IMP:02 web service and subsequently confirmed by allele specific PCR (details 
given in (22)) . HLA genotypes were categorized as shown in Table 1. A non-HLA 
T1D genetic risk score (GRS), weighted by the increased risk reported per risk allele, 
was calculated on the basis of 51 non-HLA SNPs associated with T1D (details given 
in the online supplement to (23)).  
 
Other covariates 
Information on birth weight, maternal age at delivery, and delivery mode was 
obtained from the nationwide Medical Birth Registry of Norway (24). Information 
regarding maternal pre-pregnancy body mass index (BMI) and smoking during 
pregnancy was obtained from mid-pregnancy questionnaires. The questionnaires can 
be accessed at www.fhi.no/moba. Data on maternal T1D were obtained from 
questionnaires and the Norwegian Patient Registry. The variables were categorized 
as shown in Table 1. 
 
Statistical methods 
All statistical analyses were planned a priori. We applied logistic regression with 
offspring T1D as outcome. Our main aim was to estimate the association between 
DBP levels and offspring T1D risk. Investigating the association between the 
DBP/25(OH)D ratio and T1D risk, and potential gene-environment interactions, were 
secondary aims. The main exposure was estimated average DBP (µM/L) during 
pregnancy. First, we used a linear mixed effects random intercept model, including 
DBP measurements from both maternal samples, gestational age and days since 
delivery as predictors, to predict the average maternal DBP concentration. Secondly, 
we used this predicted average as the exposure in a logistic regression analysis with 
offspring T1D as the outcome. To account for the variance in both the predicted 
average DBP and logistic regression analysis and obtain unbiased confidence 
intervals (CI), we used bootstrapping with 10 000 replicates and calculated the 
percentiles for 95% CIs for the odds ratios. The average predicted DBP was centered 
at pregnancy week 36. This centering has little or no consequences for further 
modelling and statistical significance of our results, but was chosen to better compare 
with our earlier study (10). For more details, see our earlier publication(22)We also 
investigated DBP concentration in each sample type separately (cord blood at birth, 
and maternal samples from mid-pregnancy and postpartum), DBP quartiles to assess 
linearity, and the DBP/25(OH)D ratio (used as a proxy for free 25(OH)D) in each 
sample type as exposures. The season-adjusted 25(OH)D concentration was used in 
the analysis of 25(OH)D and the 25(OH)D/DBP ratio. We tested interactions between 
25(OH)D and selected vitamin D pathway SNPs (see Supplemental Table S1), non-
HLA GRS for T1D or offspring HLA genotype. We also tested interactions between 
DBP, the GC SNP rs2282679 and offspring T1D. These interactions were chosen a 
priori on the basis of biological plausibility. 
We used clustered sandwich estimator to account for correlation between siblings. 
SNPs were coded as additive (0, 1 or 2 alleles) variables (unless combined), and 
25(OH)D and DBP levels were analyzed as continuous variables. Offspring HLA and 
T1D non-HLA GRS were included as dichotomous variables (carrying at least one 
HLA DR3-DQ2 or DR4-DQ8 haplotype vs none, and ≤median vs >median of the T1D 
non-HLA GRS in controls, respectively) in the gene-environment interaction.  
 
Adjustment variables 
The following covariates were included in our primary adjustment model: child`s HLA 
genotype, sex, cesarean delivery, maternal ethnicity, pre-pregnancy (BMI), smoking 
in pregnancy and age at delivery (see Supplemental Figure S1 for a directed acyclic 
graph of these). As a sensitivity analysis, we also included maternal T1D, birthweight, 
birth year, sample batch, and number of 25(OH)D lowering alleles in GC 
polymorphisms rs2282679 and rs222040 as adjusting variables.  
Results 
The distribution of DBP in mid-pregnancy, postpartum and cord blood samples is 
shown in Figure 2. There were weak, but statistically significant (p<0.05) correlations 
between DBP concentration in different sample types, and between DBP and 
25(OH)D in control children (Supplemental Figure S2).  
 
DBP and T1D risk 
Higher estimated average maternal DBP concentrations at gestational week 36 were 
not significantly associated with lower risk of offspring T1D, with the 95% CI including 
one (Table 2). However, when analyzing each sample type separately, higher DBP 
level in the postpartum sample was associated with lower offspring T1D risk (aOR 
0.80, 95% CI 0.67 – 0.95, p = 0.01), while DBP mid-pregnancy or in cord blood were 
not (Table 2).  
 
The 25(OH)D/DBP ratio, as a proxy for “free” 25(OH)D was not associated with 
offspring T1D risk in any sample type, with the exception of a borderline statistically 
significant association after adjustment in the post-partum sample (Table 2). This 
suggestive association disappeared after further adjustment for DBP, suggesting that 
the association with the 25OHD/DBP ratio was spurious (data not shown). Mutually 
adjusting 25(OH)D and DBP levels for each other in the same sample, or adjusting 
maternal postpartum DBP and cord blood 25(OH)D for each other, did otherwise not 
appreciably change our estimates, but resulted in wider CIs (Supplemental Table 
S2). Likewise, including more adjusting variables as a sensitivity analysis (maternal 
T1D, birthweight, birth year, sample batch or number of risk alleles in GC 
polymorphisms) did not appreciably change the estimates, but resulted in wider CIs 
(data not shown).  
 
Interactions with genetic markers 
An overall lack of associations between 25(OH)D in pregnancy, or at birth, and 
childhood T1D have been previously presented (8) (for completeness shown in 
Supplemental Table S2). In the current study, we found that the association between 
cord blood 25(OH)D and childhood T1D differed significantly by child’s VDR 
rs11568820 genotype (p[interaction]=0.01, Supplemental Table S3). Higher 25(OH)D 
levels at birth had an inverse association on offspring T1D in children homozygous 
for the VDR rs11568820 G/G genotype (Table 2). Maternal 25(OH)D remained not 
associated with offspring T1D risk in mothers or children homozygous for the 
rs11568820 G/G genotype (data not shown). No other significant interaction was 
detected between 25(OH)D and SNPs in the vitamin D pathway, vitamin D deficiency 
score, non-HLA genetic risk score for T1D or HLA genotype (Supplemental Table 
S3). Further, no interaction was detected between DBP and GC(DBP) SNP 




In this case-control study nested within a large prospective pregnancy cohort, we 
found that higher maternal DBP levels at delivery, but not in mid-pregnancy or in 
child’s cord blood, was associated with lower risk of offspring T1D. We also found 
that in children homozygous for the VDR rs11568820 G/G genotype, higher 25(OH)D 
levels at birth predicted a lower risk of developing T1D. These findings must be 
interpreted with caution, and should be replicated in independent studies.  
 
In an independent Norwegian nested case-control study, the only previous study of 
maternal DBP in relation to childhood T1D, ,  higher DBP levels in the third trimester 
were associated with decreased offspring T1D risk (10). The current study replicates 
and extends these findings by reporting that newborn (cord blood) DBP levels were 
not associated with childhood T1D risk. The current study is larger, able to control for 
additional possible confounders such as HLA genotype and BMI, and able to 
investigate possible interactions with genetic variants.  While 25(OH)D levels in 
pregnancy or at birth overall were not associated with the risk of childhood T1D (8), 
we now report that in children homozygous for the VDR rs11568820 G/G genotype, 
higher 25(OH)D levels at birth predicted decreased risk of developing T1D. We did 
not observe interactions with other SNPs previously reported to modify the effect of 
vitamin D (25), or reported to be associated with vitamin D levels or T1D(25). While 
this gene-environment finding must be interpreted with caution, Norris et al. (4) 
reported a similar interaction between 25(OH)D in early childhood and VDR genotype 
(rs7975232) in the association with islet autoimmunity. rs11568820 is believed to 
result in lower VDR expression (26). We speculate that low levels of 1,25(OH)2D and 
VDR could increase risk of autoimmunity, as they together inhibit T-cell proliferation 
(27). Increased 25(OH)D (which is correlated with 1,25(OH)2D (28)) levels in 
pregnancy could offset lower VDR expression, as 1,25(OH)2D regulates VDR 
expression (29; 30). While our study suggests an interaction with the child’s VDR 
genotype and not maternal genotype, a Finnish study reported that the maternal VDR 
SNP rs1544410 was associated with offspring T1D risk (31). No significant 
association between maternal rs1544410 and offspring T1D risk was observed in our 
study (data not shown). There are few established environmental factors associated 
with DBP levels. Interestingly, DBP has been reported to be important in production 
of the antimicrobial peptide cathelicidin in monocytes by regulating bioavailability of 
25(OH)D (32). We hypothesize that low DBP levels towards the end of pregnancy 
could influence antimicrobial response and inflammation in the mother, which could 
predispose for offspring autoimmunity. It is also plausible that another unknown factor 
operating late in pregnancy could influence both maternal DBP and offspring T1D 
risk.  
 
The gene-environment interaction observed could explain the inconsistent results of 
25(OH)D levels and T1D risk in the few previous studies in the field (8; 33; 34). 
Several polymorphisms and haplotypes in VDR have been suspected of an 
association with T1D (see (25)); rs11568820 and other polymorphisms might be 
markers of a certain VDR genotype and not be relevant to the observed association 
by themselves. Although VDR genotype was not associated with T1D in a large 
genetic study (6), a potential association could be influenced by the participants 
25(OH)D status, as suggested by Ponsonby et al. (35). Consistent with our 
observation, interactions between rs11568820 and 25(OH)D have been reported in 
colorectal cancer (36). Similarly, winter sun exposure interacted with a Cdx-2 VDR 
polymorphism in multiple sclerosis (37). Multiple sclerosis, like T1D, has an 
overrepresentation of VDR binding sites near disease-associated genetic regions (5).  
 
The association between maternal DBP levels in late pregnancy or in postpartum and 
lower offspring T1D risk, reported in this and in an independent Norwegian study (10) 
warrants further investigation regarding possible mechanisms, and replication in non-
Norwegian populations. Our data, taken together with earlier studies linking DBP to 
T1D (13-15), suggests DBP should be more intensively studied in relation to T1D. 
The interaction between the rs11568820 G/G genotype, which is the most frequent in 
our study (68.4%), cord blood 25(OH)D levels and T1D should be investigated in 
another study. If replicated, vitamin D supplementation should probably be 
recommended to all infants and pregnant women, regardless of genotype, although a 
large scale randomized controlled trial (RCT) would be ideal as a basis for 
recommendations. However, well-powered RCTs to prevent T1D are extremely costly 
and time consuming, and should therefore be carefully planned based on the best 
available preclinical and observational data. The Norwegian national guidelines 
recommend vitamin D supplementation from four weeks of age, and recommend a 
daily intake of 10 µg vitamin D in pregnant women. In the MoBa cohort, 63% of the 
mothers did not reach the recommended vitamin D intake (38), and 17% of children 
did not use vitamin D supplementation (see Table 2 in (22)), which shows that there 
is room for improvement.  
 
The strengths of this study include its prospective design and repeated 
measurements, which allowed us to assess DBP and 25(OH)D concentrations at 
different timepoints. Our large sample size with information on HLA genotype and 
genetic variation in the vitamin D pathway allowed us to examine interactions with 
genetic markers. Limitations of the study include, as in any observational study, the 
possible presence of unknown confounding factors. The nested sample was 
generally representative for the whole cohort, but our results might not be 
generalizable to the general population or populations of non-European origin. 
Further studies are needed to replicate and expand upon these findings.   
 
Our findings indicate that children whose mothers have higher DBP levels at the end 
of pregnancy are at a decreased risk of developing T1D. DBP has not been studied 
extensively in the context of T1D and more work is required to elucidate potential 
mechanism involved. Further studies in independent cohorts are need for replication 
of this observation, and experimental studies are needed to investigate potential 
mechanisms. The decreased risk of T1D for children homozygous for VDR 
rs11568820 G/G and high 25(OH)D levels at birth support the current 
recommendations for vitamin D intake for pregnant women and infants. These 
findings must be interpreted with caution and more evidence is required to validate 
these results. Regardless, potential future vitamin D studies should consider 
including VDR genotype.  
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Table 1: Characteristics of cases with childhood type 1 diabetes and randomly 
selected controls in the Norwegian Mother and Child Cohort Study. 
 
 Controls (n = 576) Cases (n = 189) 
Median age (range) at end of follow-up* (years) 11.7 (7.7–17.1) 12.7 (8.0–16.6) † 
Female sex 285 (49.5%) 93 (49.2%) 
Maternal type 1 diabetes 0 (0.0%) 7 (3.7%) 
Preterm birth 19 (3.3%) 10 (5.3%) 
Missing data 1 (0.2%) 1 (0.5%) 
Birthweight (in grams)   
<2500 g 8 (1.4%) 7 (3.7%) 
2500-4500 g 539 (93.6%) 174 (92.1%) 
>4500 g 29 (5.0%) 8 (4.2%) 
Parity   
No previous births 248 (43.1%) 93 (49.2%) 
One 215 (37.3%) 57 (30.2%) 
Two or more 113 (19.6%) 39 (20.6%) 
Maternal age in years (median, range) 30 (17–42) 30 (19–42) 
Maternal non-Norwegian ethnicity 30 (5.2%) 10 (5.3%) 
Maternal smoking during pregnancy   
Non-smoker at end of pregnancy‡ 469 (81.4%) 161 (85.2%) 
Smoked at end of pregnancy 76 (13.2%) 20 (10.6%) 
Missing data 31 (5.4%) 8 (4.2%) 
Maternal pre-pregnancy BMI (kg/m2)   
<25 379 (65.8%) 97 (51.3%) 
25-30 109 (18.9%) 49 (25.9%) 
>30 40 (6.9%) 28 (14.8%) 
Missing data 48 (8.3%) 15 (7.9%) 
Child’s HLA§ genotype and genetic risk score   
Protective (DQ6) 168 (29.2%) 3 (1.6%) 
Neutral (any other HLA not mentioned) 111 (19.3%) 5 (2.6%) 
Increased risk (≥1 copy of either DQ8 or DQ2) 212 (36.8%) 93 (49.2%) 
High risk (DQ8/DQ2 heterozygote) 30 (5.2%) 71 (37.6%) 
Missing HLA genotype 55 (9.5%) 17 (9.0%) 
Child’s  non-HLA T1D GRS|| (median, range) 61.2 (45.7 – 76.3) 63.2 (45.4 – 78.6) 
Missing non-HLA T1D GRS score 19 (3.5%) 12 (6.8%) 
Child’s  25(OH)D GRS (median, range) 3 (0 – 8) 3 (0 – 8) 
Missing 25(OH)D GRS score 20 (3.7%) 13 (7.4%) 
Caesarean section¶ 59 (10.2%) 36 (19.0%) 
* The diagnosis date of the last case included - February 3, 2014 
† The median age at diagnosis of T1D cases was 5.7 (range 0.7 – 12.7) years  
‡ Including those that quit smoking shortly before or during pregnancy 
§ Groups defined as protective (carrying at least one copy of HLA DQA1*01:02-DQB1*06:02-
DRB1*15:01 [DQ6-DR15]), increased risk (at least one copy of HLA DQA1*03-DQB1*03:02-
DRB1*04 [DQ8-DR4] or DQA1*05:01-DQB1*02:01-DRB1*03:01 [DQ2-DR3], but not both 
haplotypes), high risk (HLA DQ2-DR3/DQ8-DR4) or neutral (any other genotype). 
|| Weighted score, calculated by multiplying the number of risk alleles in 51 non-HLA SNPs 
with their reported risk per allele. 
¶ Includes unknown (n = 1), emergency (n = 55) and elective (n = 39) caesarean section  
Table 2: Association between exposures and type 1 diabetes 
DBP, per 1 µM/L increase OR, 95% CI aOR, 95% CI* P-value 
Predicted maternal DBP† 0.74 (0.39 – 1.22) 0.49 (0.18 – 1.02) n.s ‡ 
Mid-pregnancy 1.03 (0.91 – 1.16) 0.96 (0.79 – 1.16) 0.65 
Cord blood 0.98 (0.81 – 1.20) 0.87 (0.67 – 1.14) 0.32 
Postpartum 0.86 (0.74 – 0.98) 0.80 (0.67 – 0.95) 0.01 
25(OH)D / DBP ratio    
Mid-pregnancy 1.00 (0.96 – 1.04) 1.04 (0.98 – 1.09) 0.17 
Cord blood 0.99 (0.97 – 1.01) 1.00 (0.97 – 1.04) 0.81 
Postpartum 1.01 (0.98 – 1.04) 1.05 (1.00 – 1.10) 0.049 
25(OH)D, per 10 nmol/L increase, stratified by VDR rs11568820§  
Cord blood, AA/AG 1.18 (1.00 – 1.40) 1.17 (0.95 – 1.44) 0.15 
Cord blood, GG  0.87 (0.77 – 0.98) 0.85 (0.72 – 1.00) 0.047 
 
aOR: adjusted Odds Ratio; CI: Confidence Interval. P-value shown for adjusted 
analysis.  
* adjusted for child`s HLA genotype, sex, maternal ethnicity, age, pre-pregnancy BMI, 
caesarean section and smoking. 
† using maternal (mid-pregnancy and postpartum) samples in a mixed model to 
predict maternal DBP values at gestational week 36. Due to the reduction of the 
sampling variation when predicting maternal DBP, the predicted values have a lower 
standard deviation (SD) of 0.35 (while e.g. DBP in the postpartum samples has a SD 
of 1.52).This results in a greater observed estimate, as an increase per unit is roughly 
equivalent to 3 standard deviations in this analysis. We used bootstrapping (10 000 
replications) to obtain un-biased CIs, and present bias-corrected CIs.  
‡ as these results arise from bootstrapping estimations, a p-value is not provided.  
§ there was a statistically significant interaction (p[interaction]=0.01) between 




Figure 1: Formation of the analysis sample 
* : 148 had 3 blood samples, 38 had 2 blood samples and 3 had one blood sample 
available for 25(OH)D and DBP testing. There were 174 mid-pregnancy, 174 
postpartum and 175 cord blood samples. 
† : 456 had 3 blood samples, 111 had 2 blood samples and 9 had one blood sample 
available for 25(OH)D and DBP testing. There were 532 mid-pregnancy, 525 
postpartum and 542 cord blood samples. 
 
Figure 2: Distribution of vitamin D-binding protein (DBP) concentrations in 
maternal and cord blood plasma samples. 
Figure 2 shows the distribution of vitamin D-binding protein (DBP) concentrations in 
maternal and cord blood plasma samples from randomly selected controls (n=576) in 
the Norwegian Mother and Child Cohort Study. The maternal delivery (postpartum) 
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Supplemental Figure 1 shows a hypothetical Directed Acyclic Graph to illustrate how we 
hypothesized the relationships between DBP, adjustment covariates and Type 1 diabetes.  




This figure shows Spearmans’ rho between 25(OH)D (deseasonalized) and DBP z-
scores in control children (as correlation estimates based on cases can be biased). 
Cord blood and postpartum 25(OH)D have high correlation (0.72), with the rest 
having weaker correlations. All correlations above 0.1 were significant (p<0.05). 
 
  
Supplemental Table S1: 25(OH)D 
metabolism SNPs  
SNP* Gene Genotype Child N(%) Maternal N(%) 
rs10741657 CYP2R1 AA 81 (14.9%) 65 (12.2%) 
  AG 252 (46.3%) 248 (46.4%) 
  GG 192 (35.3%) 198 (37.1%) 
  Missing 19 (3.5%) 23 (4.3%) 
rs703842 CYP27B1 AA 204 (37.5%) 199 (37.3%) 
  AG 257 (47.2%) 253 (47.4%) 
  GG 63 (11.6%) 58 (10.9%) 
  Missing 20 (3.7%) 24 (4.5%) 
rs6013897 CYP24A1 AA 323 (59.4%) 300 (56.2%) 
  AT 180 (33.1%) 178 (33.3%) 
  TT 22 (4.0%) 33 (6.2%) 
  Missing 19 (3.5%) 23 (4.3%) 
rs2282679† GC(DBP) AA 293 (53.9%) 282 (52.8%) 
  AC 185 (34.0%) 195 (36.5%) 
  CC 47 (8.6%) 35 (6.6%) 
  Missing 19 (3.5%) 22 (4.1%) 
rs12785878 DHCR7 AA 244 (44.9%) 228 (42.7%) 
  AC 223 (41.0%) 238 (44.6%) 
  CC 58 (10.7%) 46 (8.6%) 
  Missing 19 (3.5%) 22 (4.1%) 
rs1544410 VDR‡ AA 177 (32.5%) 172 (32.2%) 
  AG 246 (45.2%) 239 (44.8%) 
  GG 101 (18.6%) 100 (18.7%) 
  Missing 20 (3.7%) 23 (4.3%) 
rs11568820 VDR§ AA 22 (4.0%) 11 (2.1%) 
  AG 131 (24.1%) 144 (27.0%) 
  GG 372 (68.4%) 355 (66.5%) 
  Missing 19 (3.5%) 24 (4.5%) 
 
N and % calculated from control mother and child dyads. 
* In addition the following SNPs were tested, but not used for further analyses due to 
linkage disequilibrium with other SNPs for the respective loci; CYP2R1: rs2060793 
and rs12794714; CYP27B1: rs4646536; GC: rs222040 and rs1352846; DHCR7: 
rs3829251  
† rs2282679 is a near perfect proxy for the coding SNP rs4588. rs2282679 C allele is 
linked to lower serum 25(OH)D levels. 
‡ Also known as VDR-BsmI polymorphism 
§ Also known as VDR-CdX2 polymorphism  
Supplemental Table S2: Supplemental 
Results 




OR, 95% CI aOR, 95% CI* P-value 
Mid-pregnancy 174/531 1.00 (0.99 – 1.01) 1.01 (1.00 – 1.01) 0.23 
Cord blood 175/542 1.00 (0.99 – 1.01) 0.99 (0.98 – 1.01) 0.38 
Postpartum 174/524 1.00 (0.99 – 1.01) 1.00 (0.99 – 1.01) 0.75 
25(OH)D and DBP mutually adjusted  
25(OH)D, cord blood 174/537 0.99 (0.97 – 1.00) 0.99 (0.97 – 1.00) 0.12 
DBP, cord blood 0.98 (0.73 – 1.30) 0.90 (0.63 – 1.30) 0.58 
25(OH)D, cord blood 162/494 1.00 (0.99 – 1.01) 0.99 (0.98 – 1.01) 0.42 
DBP, postpartum 0.89 (0.77 – 1.02) 0.83 (0.69 – 1.00) 0.047 
Mutually adjusted, restricted to VDR rs11568820 GG genotype† 
25(OH)D, cord blood 112/367 0.99 (0.97 – 1.00) 0.99 (0.97 – 1.00) 0.12 
DBP, cord blood 0.98 (0.73 – 1.30) 0.90 (0.63 – 1.30) 0.58 
25(OH)D, cord blood 105/335 0.99 (0.97 – 1.00) 0.98 (0.96 – 1.00) 0.08 
DBP, postpartum 0.90 (0.75 – 1.08) 0.82 (0.65 – 1.03) 0.09 
 
aOR: adjusted Odds Ratio; CI: Confidence Interval 
* adjusted for child`s HLA genotype, sex, maternal ethnicity, age, pre-pregnancy BMI, 
caesarean section and smoking. 
† the number of cases and controls included in the unadjusted analysis. 
 
  
Supplemental Table S3: Gene – 
Environment interactions 
 
Exposure SNP  Interaction estimate (95% CI) p-value 
Maternal* 25(OH)D CYP2R1 -rs10741657 1.00 (0.99 - 1.01) 0.84 
 CYP27B1 - rs703842 1.00 (0.99 - 1.02) 0.68 
 CYP24A1 - rs6013897 1.01 (0.99 - 1.02) 0.39 
 GC(DBP) - rs2282679 1.00 (0.98 - 1.01) 0.77 
 DHCR7 - rs12785878 1.01 (1.00 - 1.02) 0.13 
 VDR - rs1544410 1.00 (0.98 - 1.01) 0.44 
 VDR - rs11568820 1.00 (0.99 - 1.02) 0.84 
 25(OH)D GRS† 1.00 (0.99 -1.01) 0.74 
Offspring 25(OH)D CYP2R1 -rs10741657 1.01 (0.99 - 1.02) 0.39 
 CYP27B1 - rs703842 0.99 (0.98 - 1.01) 0.52 
 CYP24A1 - rs6013897 1.01 (0.99 - 1.03) 0.37 
 GC(DBP) - rs2282679 1.00 (0.98 - 1.02) 0.87 
 DHCR7 - rs12785878 1.00 (0.98 - 1.02) 0.90 
 VDR - rs1544410 0.99 (0.98 - 1.01) 0.50 
 VDR - rs11568820 0.98 (0.96 - 0.99) 0.01 
 25(OH)D GRS† 1.00 (0.99 -1.01) 0.74 
 Non-HLA GRS‡ 1.00 (1.00 -1.00) 0.23 
 HLA§ 1.00 (0.96 - 1.05) 0.80 
 
CI: confidence interval 
*: Tested in mid-pregnancy sample. 
†: a risk score for low vitamin D levels, calculated by summing the risk alleles in non-
VDR SNPs shown above. See [1] for detail.  
‡: non-HLA genetic risk score, calculated by multiplying the number of risk alleles 
with the OR for type 1 diabetes per each established non-HLA risk SNP (n=51), then 
summing this per child. Please see our previous publication [2] for a list of non-HLA 
risk SNPs for type 1 diabetes and their ORs. 
§: Coded as dichotomous variable: protective or baseline vs risk (carrying at least 
one HLA DR3-DQ2 or DR4-DQ8 allele) 
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